Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.5582/ddt.2021.01058 http://scihub22266oqcxt.onion/10.5582/ddt.2021.01058 34234059!?!34234059 Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=34234059&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Drug+Discov+Ther 2021 ; 15 (3): 118-123 Nephropedia Template TP {{tp|p=34234059|t=2021. Next-generation COVID-19 vaccines: Opportunities for vaccine development and challenges in tackling COVID-19 |pdf=|usr=}}{{34234059}} gab.com Text Next-generation COVID-19 vaccines: Opportunities for vaccine development and challenges in tackling COVID-19 JO: Drug Discov Ther http://www.kidney.de/pget.php?&tw=1&pmid=34234059 #FOAvip The ongoing COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a global threat. Although non-pharmaceutical interventions have been rigorously and widely implemented, living conditions caused by the pandemic will last until highly effective vaccines are successfully improved and globally administered. Several first-generation COVID-19 vaccines were approved at the end of 2020. However, the COVID-19 pandemic is persisting worldwide. To be clear, the efficiency and the coverage of current vaccines are insufficient, but newly emerging and rapidly spreading variants are the most pressing concern. A second-generation COVID-19 vaccine worth mentioning, NVX-CoV2373, has demonstrated 90% overall efficacy as well as a high level of efficacy against circulating variants in Phase 3 clinical trials. Currently, NVX-CoV2373 is the only vaccine that has proven successful against variants during Phase 3/4 trials. Therefore, developing the next generation of vaccines is a promising strategy to ultimately prevail against SARS-CoV-2. This review provides up-to-date information on COVID-19 vaccines in terms of their efficacy and new platforms and the progression of COVID-19 vaccination. Moreover, this review also summarizes the efficacy of approved COVID-19 vaccines against variants. Lastly, this review highlights the global challenges for COVID-19 vaccines in development and vaccination, and it discusses opportunities for development of future COVID-19 vaccines and vaccination coverage. Twit Text FOAVip Next-generation COVID-19 vaccines: Opportunities for vaccine development and challenges in tackling COVID-19 ????Drug Discov Ther http://www.kidney.de/pget.php?&tw=1&pmid=34234059 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34234059 #FOAvip English Wikipedia <ref>{{Cite pmid|34234059}}</ref> Next-generation COVID-19 vaccines: Opportunities for vaccine development and challenges in tackling COVID-19 #MMPMID34234059 Li Q; Wang J; Tang Y; Lu H Drug Discov Ther 2021[]; 15 (3): 118-123 PMID34234059show ga The ongoing COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a global threat. Although non-pharmaceutical interventions have been rigorously and widely implemented, living conditions caused by the pandemic will last until highly effective vaccines are successfully improved and globally administered. Several first-generation COVID-19 vaccines were approved at the end of 2020. However, the COVID-19 pandemic is persisting worldwide. To be clear, the efficiency and the coverage of current vaccines are insufficient, but newly emerging and rapidly spreading variants are the most pressing concern. A second-generation COVID-19 vaccine worth mentioning, NVX-CoV2373, has demonstrated 90% overall efficacy as well as a high level of efficacy against circulating variants in Phase 3 clinical trials. Currently, NVX-CoV2373 is the only vaccine that has proven successful against variants during Phase 3/4 trials. Therefore, developing the next generation of vaccines is a promising strategy to ultimately prevail against SARS-CoV-2. This review provides up-to-date information on COVID-19 vaccines in terms of their efficacy and new platforms and the progression of COVID-19 vaccination. Moreover, this review also summarizes the efficacy of approved COVID-19 vaccines against variants. Lastly, this review highlights the global challenges for COVID-19 vaccines in development and vaccination, and it discusses opportunities for development of future COVID-19 vaccines and vaccination coverage. |COVID-19 Vaccines/*administration & dosage[MESH] |COVID-19/*prevention & control/virology[MESH] |Clinical Trials as Topic[MESH] |Humans[MESH]Next-generation COVID-19 vaccines: Opportunities for vaccine developme(epmc).pdf DeepDyve Pubget Overpricing